- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Journal: Interdigitation of lipids for vesosomal formulation of ergotamine tartrate with caffeine: A futuristic trend of intranasal route. (Pubmed Central) - Jan 2, 2024
Objective: This research work aimed to form vesosomes using combination of two drugs ergotamine and caffeine for synergistic activity when given intranasally resulting in faster absorption, steric stability and controlled release.Significance: The multicompartment vesicles viz., vesosomes of ergotamine tartrate proved to increase absorption of drugs post-intranasal administration, bypassing the blood-brain barrier via the olfactory pathway The phospholipids like soya lecithin, cholesterol and dipalmitoyl phosphatidylcholine were used to form a multicompartment structure called vesosomes using ethanol-induced interdigitation of lipids as the preparation method. The formulation showed low particle size of 315.48?
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Journal: Potentially Inappropriate Use of Opioids in the Management of Migraine in Colombia. (Pubmed Central) - Sep 28, 2023
The frequent use of opioids in the management of migraines is potentially inappropriate and can lead to problems of tolerance, abuse and dependence. This combined with the low prescription of triptans, offers an opportunity for improvements in medical practice.
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Journal: Use of 3D applicator for intranasal microneedle arrays for combinational therapy in migraine. (Pubmed Central) - Mar 20, 2023
The novel 3D applicator effectively delivered the microneedle array into the nasal cavity for systemic action. Therefore, the fabricated rapid dissolving microneedles combining two drugs ergotamine and caffeine with use of 3D applicator proved to be a coherent technique for intranasal delivery of ergotamine in the treatment of migraine.
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Journal: Self-Assembled Lipid Polymer Hybrid Nanoparticles Using Combinational Drugs for Migraine Via Intranasal Route. (Pubmed Central) - Dec 18, 2022
Histopathological investigations and serotonin toxicity studies in animals confirmed the safe and non-toxic nature of the formulation while the acetic acid writhing test proved the anti-hyperalgesic activity. The PEGylated lipid polymer hybrid nanoparticles of ergotamine and caffeine showed synergistic activity with efficacious higher anti-migraine potential.
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Journal: 2022 Taiwan Guidelines for Acute Treatment of Migraine. (Pubmed Central) - Sep 30, 2022
Evidence supporting the use of intravenous tramadol or morphine is insufficient; therefore, their use is not recommended...For moderate to severe attacks, oral or nasal spray triptans and ergotamine/caffeine compounds are recommended and should be administered in the early stage of migraine attacks...To prevent medication overuse headache, the use of acute treatment should be limited to a maximum of 2 days per week. Key words: acute migraine treatment, evidence-based medicine, treatment guidelines, triptans, ergotamine, neuromodulation.
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
PK/PD data, Journal: Tracing the influence of caffeine on the pharmacokinetic parameters of three headache relieving pharmaceuticals applying synchronous fluorescence spectroscopy. (Pubmed Central) - Aug 12, 2022
A simple, sensitive, and selective first derivative synchronous fluorimetric method was developed and optimized to track the influence of caffeine content in beverages on the pharmacokinetic parameters of three pharmaceuticals used in relieving headache namely, aspirin (ASP), ibuprofen (IBU), and ergotamine tartrate (ERG)...Moreover, the developed bioanalytical method was subjected to full validation to avoid interferences emerging from biological matrices. The greenness of the proposed method was assessed according to the Analytical Eco-Scale and proved to be excellent green carrying a score of 98%.
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Clinical, Review, Journal: The effects of caffeine in adults with neurogenic orthostatic hypotension: a systematic review. (Pubmed Central) - Nov 29, 2021
The greenness of the proposed method was assessed according to the Analytical Eco-Scale and proved to be excellent green carrying a score of 98%. Caffeine should only be considered as a treatment for adults with neurogenic orthostatic hypotension when evidence-based treatments have been exhausted.
- |||||||||| Reyvow (lasmiditan) / Eli Lilly, Ergonex (ergotamine/caffeine) / AC Farma
Clinical, Retrospective data, Review, Journal: Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. (Pubmed Central) - Jul 7, 2021
Use of triptans, nonsteroidal anti-inflammatory drugs, acetaminophen, dihydroergotamine, calcitonin gene-related peptide antagonists, lasmiditan, and some nonpharmacologic treatments was associated with improved pain and function. The evidence for many other interventions, including opioids, was limited.
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
[VIRTUAL] Overt ergotism due to overuse of ergotamine-caffeine () - Jun 4, 2021 - Abstract #AHS2021AHS_166;
ergotamine exerts effects on multiple neurotransmitter pathways including norepinephrine and dopamine that can result in vasoconstriction and nausea/vomiting, respectively. The use of ergotamine is recommended only to a subset of patients given its significant side effect profile.
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Phase classification, Enrollment change: Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) - Jan 18, 2017
P1, N=389, Completed,
Validation parameters were checked according to International Conference of Harmonization guidelines to achieve the international requirements for quality control analysis of the proposed drugs. Phase classification: P3 --> P1 | N=80 --> 389
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Trial completion, Enrollment change, Trial primary completion date: Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) - Jan 17, 2017
P3, N=80, Completed,
Phase classification: P3 --> P1 | N=80 --> 389 Recruiting --> Completed | N=500 --> 80 | Trial primary completion date: Apr 2017 --> Jan 2017
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Trial primary completion date: Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) - Apr 28, 2016
P3, N=500, Recruiting,
Recruiting --> Completed | N=500 --> 80 | Trial primary completion date: Apr 2017 --> Jan 2017 Trial primary completion date: Apr 2016 --> Apr 2017
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Trial primary completion date: Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) - Jun 11, 2015
P3, N=500, Recruiting,
Trial primary completion date: Apr 2016 --> Apr 2017 Trial primary completion date: May 2015 --> Apr 2016
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Trial primary completion date: Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) - May 1, 2014
P3, N=500, Recruiting,
Trial primary completion date: May 2015 --> Apr 2016 Trial primary completion date: May 2014 --> May 2015
- |||||||||| Ergonex (ergotamine/caffeine) / AC Farma
Trial completion date: Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) - May 1, 2014
P3, N=500, Recruiting,
Trial primary completion date: May 2014 --> May 2015 Trial completion date: May 2014 --> May 2016
|
